Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Elevated Intraocular Pressure

Interventions

DRUG: Latanoprost ophthalmic solution, 0.005%
DRUG: TC-002 latanoprost ophthalmic solution, 0.005%

Sponsor

TearClear Corp